Growth in Medical Technology

TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men

PHOENIX, Aug. 3 /PRNewswire-USNewswire/ -- The Phoenix-based Kronos Longevity Research Institute (KLRI) has published two new publications on hormone therapies and their effects on reducing the risks of cardiovascular disease in older adults. Cardiovascular disease caused by ...

Scientists Discover a Role for the Growth Factor TGF-beta in Maintaining Health of Retinal Blood Vessels

BOSTON, April 7 /PRNewswire-USNewswire/ -- Scientists at Schepens Eye Research Institute have found that the growth factor known as TGF-beta is essential to the health of blood vessels in the retina and that blocking it can cause retinal dysfunction. These findings, published in the April 2 is...

Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP

- Single Injection in Primates Containing 1,000-Times the Dosage Recommended for Humans Shows No Adverse Effects - - Half-Life and AUC Support the Potential for Weekly or Bi-Monthly Dosing Frequency - NES-ZIONA, Israel, Jan. 15 /PRNewswire-FirstCall/ -- Modigene Inc. (OTC Bulletin Board:...

New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors

- Data show significant 66% reduction in risk of disease progression versus placebo - Sandostatin LAR more than doubled time without tumor growth for a median of 14 months compared to six months on placebo - Results support Sandostatin LAR as first treatment after surgery in certain pati...

Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies

SAN MARINO, Calif., Nov. 20 /PRNewswire/ -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meet...

Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy

Quark siRNAs Examined Alone and in Combination with Chemotherapy FREMONT, Calif. Oct. 12 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that the journal Cance...

Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer

- New data, updated since ASCO, show time without tumor growth now reaches nearly 5 months with RAD001 vs. 1.9 months with placebo - One quarter of patients in trial remained progression-free beyond ten months of treatment - RAD001 is first drug to show significa...

RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors

- 82% of patients with pancreatic neuroendocrine tumors (NET) experienced clinical benefit when treated with daily RAD001 and monthly Sandostatin LAR Depot - 77% of patients with pancreatic NET experienced clinical benefit when treated with ...

Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market

Owing to Well-Established and Effective Insulin-Based Therapies, Market Growth Will be Modest Through 2017, According to a New Report from Decision Resources WALTHAM, Mass., Aug. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and adviso...

Protein Key to Control Growth of Blood Cells

--Findings May Aid in Bone Marrow Transplants, Blood Diseases-- PHILADELPHIA, Aug. 5 /PRNewswire-USNewswire/ -- New research sheds light on the biological events by which stem cells in the bone marrow develop into the broad variety of cells that circulate in the blood. The findings may hel...

Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters

Company Focused on IND-Enabling Work with Protein Therapeutics that Modulate Alternative Pathway of Complement System CAMBRIDGE, Mass., July 23 /PRNewswire/ -- Taligen Therapeutics Inc. today announced it has initiated a corporate growth plan with the appointment of Abbie Celniker,...

RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer

- RECORD-1 trial shows RAD001 reduces risk of disease progression by 70% - RAD001 is first and only drug to show significant benefit after failure of approved therapies Sutent(R) or Nexavar(R),** with potential to address unmet medical need - Once-daily oral RAD001 di...

Pharmacyclics' Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer

SAN DIEGO and SUNNYVALE, Calif., April 16 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today presented preclinical results demonstrating the anti-tumor activity of PCI-27483, the company's small-molecule Factor VIIa inhibitor. The data were presented during the Annual Meeting...

Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer

-No Metastatic Lesions Were Detectable After Combination Therapy Treatment- -Survival Time More Than Doubled in Animals Treated with Combination Therapy- -Established Tumors Regressed by 50% After Combination Therapy Treatment- SAN DIEGO and TUSTIN, Calif., April...

BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies

- BiPar Sciences Presents First Peer-Reviewed Preclinical Results for BSI-201 at 2008 AACR Annual Meeting - SAN DIEGO, April 14 /PRNewswire/ -- BiPar Sciences, Inc. today announced positive preclinical data demonstrating the activity of its lead poly ADP-ribose polymerase (PAR...

New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ

BRIDGEWATER, N.J., March 15 /PRNewswire-FirstCall/ -- Data presented at the annual meeting of the American Academy of Allergy Asthma & Immunology (AAAAI) suggests that the continuous use of intranasal corticosteroid Nasacort AQ (triamcinolone acetonide) Nasal Spray had no treatment effect on s...

St. Jude Finds Signaling System That Halts the Growth of a Childhood Brain Cancer

Researchers discover that proteins BMP2, BMP4 and BMP7 inhibit the growth of medulloblastoma tumors, while inducing malignant cells to develop into normal neurons, a finding that may lead to better treatments for the cancer MEMPHIS, Tenn., March 14 /PRNewswire-USNewswire/ -- A discovery by...

Rapid Growth of Asia-Pacific Clinical Trials Market Focus of New CenterWatch Report

BOSTON, Feb. 6 /PRNewswire/ -- CenterWatch, a publishing and information services company focused on market research about clinical trials, finds in a new report that the Asia-Pacific region is grabbing an increasing share of the global clinical trial market, and with new regulatory changes ac...

HealthMedia's Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships

Health care license revenue increases more than 100% in third quarter ANN ARBOR, Mich., Dec. 20 /PRNewswire/ -- HealthMedia, the global leader in scalable behavior change interventions with outcomes, secured several new partnerships and continued to experience rapid growth throughout the thir...

NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models

Anti-Tumor Activity of NKTR-102 Associated With Increased and Sustained Exposure of Tumor Tissue to the Active Metabolite of Irinotecan SAN FRANCISCO, Oct. 25 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) presented positive preclinical data today on its proprietary product ...

Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference

SAN CARLOS, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that preclinical data for its proprietary product candidate NKTR-102 (PEG-irinotecan) will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Th...

Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference

NEW YORK, Oct. 1 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced that I. Craig Henderson, MD, the Company's President, will present an overview of the Company's cancer pipeline at the upcoming William Blair & Company Small-Cap Growth Stock Conference i...

Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells

New "Oxygen Sandwich" Device is First to Mimic Natural Physical Environment MIAMI, Sept. 5 /PRNewswire/ -- One of the major challenges to islet cell transplantation as the treatment of choice for type 1 diabetes is the shortage of donor tissue supply. Patients often need a re-infusion of islet c...

Pivotal Clinical Data Published for the Only Laser Phototherapy Device Cleared by the FDA for Hair Growth

- Study provides clinical efficacy of the HairMax LaserComb in the treatment of Androgenetic Alopecia in males commonly known as 'male pattern baldness' - BOCA RATON, Fla., April 20 /PRNewswire/ -- Findings of the pivotal clinical trial of the HairMax LaserComb that provided clear evidence ...

Discovery of Marker for Colon Stem Cells Could Shed Light on What Drives Tumor Growth

WILMINGTON, Del., April 7 /PRNewswire/ -- Cancer researchers led by Bruce Boman, M.D., Ph.D. director of Cancer Genetics and Stem Cell Biology at the Helen F. Graham Cancer Center of the Christiana Care Health System, and a faculty member at the University of Delaware , have discovered an enzyme ...

CyberKnife Radiosurgery for Lung Cancer Sees Increased Interest and Continued Rapid Growth

SUNNYVALE, Calif., March 2 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY ), a global leader in the field of radiosurgery, announced today significant growth in CyberKnife lung cancer treatments in calendar year 2008. The number of lung cancer patients treated with CyberKnife radi...

Alzheimer's Growth Shows Need for Increased FDA Funding

Coalition for a Stronger FDA says drug review programs need more money WASHINGTON, March 21, 2007 /PRNewswire-USNewswire/ -- A new estimate by the Alzheimer's Association shows that more than five million Americans are living with Alzheimer's disease -- a 10 percent growth over previous estimates ...

Preclinical Data Show Alfacell's Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells

Poster Presented at AACR Annual Meeting BLOOMFIELD, N.J., April 16, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today announced that in vivo and in vitro preclinical data presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting show that ONCONASE (ranpirn...

Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies

- Combination Therapy Significantly Decreased Tumor Blood Vessel Density and Serum PSA Levels in Prostate Tumors - LOS ANGELES and TUSTIN, Calif., April 17, 2007 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing targeted monoclonal an...

Data Presented at AACR Meeting Shows Peregrine's Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies

- New Studies Confirm That Fusion Proteins Made by Combining Cytokines With Peregrine's Anti-PS Antibodies Demonstrate Increased Anti-Tumor Activity With No Observable Toxicity - LOS ANGELES and TUSTIN, Calif., April 18, 2007 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a clinical s...

Doctors Outraged Over Growth Hormone Controversy

Two anti-aging preventative medicine doctors say they are outraged over recent media coverage about their advocacy of prescribing human growth hormone to treat a hormone deficiency often associated with aging. DAYTONA BEACH, Fla., April 27, 2007 /PRNewswire/ -- The adult use of human growth hormon...

Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin

VIENNA, Va., June 20, 2007 /PRNewswire/ -- Modigene Inc., a Nevada corporation today announced the successful completion of pharmacokinetic and pharmacodynamic pre-clinical experiments for long-acting human growth hormone, long-acting interferon beta and long-acting erythropoietin. Modigene's ph...

New Report 'Looking at Chiral Technologies' Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals

DUBLIN, Ireland--(BUSINESS WIRE)--Jun 21, 2007 - Research and Markets (http://www.researchandmarkets.com/reports/c60415) has announced the addition of Looking at Chiral Technologies to their offering. The advancements in molecular research and continued untiring efforts of the research industry to...

Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference

RICHMOND, VA., July 9 /CNW/ - Insmed Inc. (NASDAQ:INSM), a biopharmaceutical company focused on the development and approval of drugs for the treatment of metabolic diseases with unmet medical needs, today announced that it will present at this week's C.E. Unterberg, Towbin (CEUT) Emerging Grow...

Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference

FORT LEE, N.J.--(BUSINESS WIRE)--Jul 6, 2007 - Neurologix, Inc. (OTCBB:NRGX), a biotechnology company engaged in the development of innovative gene therapies for the brain and central nervous system, announced today that the company will present at the Third Annual C.E. Unterberg Towbin Emerging Gr...

Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference

BETHESDA, Md., July 05, 2007 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, today announced that Dr. Christian Itin, President and Chief Executive Off...

GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Jul 5, 2007 - GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today that Geoffrey Cox, Ph.D., GTC's Chairman and CEO, is scheduled to present on Wednesday, July 11, 2007 at 9:00 a.m. during the C.E. Unterberg, Towbin Emerging Growth Life Opportunities C...

Rosetta Genomics to Webcast Presentation at CE Unterberg, Towbin Emerging Growth Opportunities Conference

REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, July 03, 2007 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd , a leading microRNA company, announced today that J. Michael French, Rosetta Genomics President, will present at CE Unterberg, Towbin Emerging Growth Opportunities Conference on Tuesday, ...

EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Jul 3, 2007 - EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX) today announced that Michael G. Kauffman, M.D., Ph.D., chief executive officer of EPIX, is scheduled to present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference on Tuesday, July 10, 2007 ...

Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference

SOUTH SAN FRANCISCO, Calif., July 03, 2007 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. today announced that Eric Bjerkholt, Sunesis' Senior Vice President, Corporate Development and Finance, will present a company update at the C. E. Unterberg, Towbin Emerging Growth Conference on July...